ASGCT 2021 | Virtual Meeting
We’re looking forward to the ASGCT 2021 Virtual Meeting being held held May 11-14, 2021. We have a number of presentations and sessions scheduled:
VIRTUAL PRESENTATION
Development of a Split Rep/Cap System to Improve AAV Capsid Production
Presenter: Derek Carbaugh, R&D, Asklepios BioPharmaceutical, Inc.
Session: Novel AAV Biology and Platform Technologies
Date/Time: Thursday, May 13, 2021 5:45 p.m. ET – 6:00 p.m. ET
Abstract Number: 188
POSTER PRESENTATIONS
The Key Amino Acids Play a Critical Role in the Production of the Haploid Adeno-Associated Virus
Presenter: Zheng Chai, R&D, Asklepios BioPharmaceutical, Inc.
Session: AAV Vectors – Virology and Vectorology
Date/Time: Tuesday, May 11, 2021 8:00 a.m. ET
Abstract Number: 297
Evaluating Partner Fitness by Interfaces Interaction in Potential AAV Haploids
Presenter: Amaury Pupo, R&D, Asklepios BioPharmaceutical, Inc.
Session: AAV Vectors – Virology and Vectorology
Date/Time: Tuesday, May 11, 2021 8:00 a.m. ET
Abstract Number: 300
Novel and Highly Potent Selective Synthetic Promoters for Muscle-Directed Gene Therapy Applications
Presenter: J. Omar Yanez-Cuna, Product R&D, Asklepios BioPharmaceutical, Inc.
Session: Musculo-skeletal Diseases
Date/Time: Tuesday May 11, 2021 8:00 AM – 10:00 AM
Abstract Number: 612
Generation and Characterization of GAA Knock Out HepG2 Cell Line
Presenter: Bikash Shakya, R&D, Asklepios BioPharmaceutical, Inc.
Session: Musculo-skeletal Diseases
Date/Time: Tuesday, May 11, 2021 8:00 a.m. ET
Abstract Number: 615
Effect of Peptide-Based Inhibition of DNase II on AAV Transduction and TLR9 Signaling
Presenter: Audry Fernandez, R&D, Asklepios BioPharmaceutical, Inc.
Session: Immunological Aspects of Gene Therapy and Vaccines
Date/Time: Tuesday, May 11, 2021 8:00 a.m. ET
Abstract Number: 744
EDUCATION SESSION
Development Pipeline – AAV Vectors for Pompe/CNS
Presenter: Nathalie Cartier-Lacave, M.D., Asklepios BioPharmaceuticals
Session: AAV Vectors From Basic Biology to Clinical Application and Back
Date/Time: Tuesday, May 11, 2021 4:05 p.m. ET – 4:40 p.m. ET
SCIENTIFIC SYMPOSIA
Human Immune Response to AAV Vectors
Presenter: Katherine High, M.D., President, Therapeutics, Asklepios BioPharmaceuticals
Session: Viral Vector Safety: A Renewed Focus on Vector Safety and Innate
Immune Responses to Leading Viral Vectors
Date/Time: Thursday, May 13, 2021 10:21 a.m. ET – 10:42 a.m. ET
PANEL DISCUSSION
Tim Kelly, AskBio’s President of Manufacturing, will participate in a panel discussion, “Considerations for the Clinical Development of Cell & Gene Therapies.” The panel discussion among industry leaders will take place on Tuesday, May 11, 2021 from 6:00 p.m. ET – 6:45 p.m. ET.
